Comparative Anti-Inflammatory Effect of Aceclofenac-Saccharin in Mice Granuloma Model

Authors

  • Hendrizal Usman Department of Pharmacy, Faculty of Pharmacy Science and Technology, Padang, West Sumatera, Indonesia
  • Yufri Aldi Department of Pharmaceutic, Faculty of Pharmacy, Universitas Andalas, Padang, West Sumatera, Indonesia
  • Salman Umar Department of Pharmaceutic, Faculty of Pharmacy, Universitas Andalas, Padang, West Sumatera, Indonesia
  • Rahmadevi Department of Pharmaceutic, Faculty of Pharmacy, Universitas Andalas, Padang, West Sumatera, Indonesia
  • Erizal Zaini Department of Pharmaceutic, Faculty of Pharmacy, Universitas Andalas, Padang, West Sumatera, Indonesia

DOI:

https://doi.org/10.15408/pbsj.v7i1.49145

Keywords:

Aceclofenac-Saccharin, Anti-inflammatory, Exudate volume, ; Granuloma pouch, TNF-α

Abstract

Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) and suppresses prostaglandin synthesis. Its clinical utility, however, is limited by poor aqueous solubility and low bioavailability. This study evaluates the anti-inflammatory activity of a multicomponent crystal (MC) of aceclofenac with saccharin using a carrageenan-induced granuloma pouch model in mice. Male mice were divided into three groups (n = 3 per group): control, aceclofenac, and aceclofenac-saccharin multicomponent crystal, administered intraperitoneally. Inflammatory response was assessed via exudate volume and TNF-α levels. Both aceclofenac and MC significantly reduced exudate volume and TNF-α compared to the control (p < 0.05), with the MC group showing the greatest reduction. Although not statistically different from aceclofenac in TNF-α suppression, the MC demonstrated superior performance overall. The enhanced efficacy may be attributed to improved solubility and drug delivery. These outcomes support co-crystallization as a promising approach to optimize NSAID therapy.

References

Chun, N.H., Wang, I.C., Lee, M.J., Jung, Y.T., Lee, S., Kim, W.S. & Choi, G.J., 2013. Characteristics of indomethacin-saccharin (IMC-SAC) co-crystals prepared by an anti-solvent crystallization process. European Journal of Pharmaceutics and Biopharmaceutics, 85(3), pp.854-861.

Connor, L.E., Vassileiou, A.D., Halbert, G.W., Johnston, B.F. & Oswald, I.D.H., 2019. Structural investigation and compression of a co-crystal of indomethacin and saccharin. CrystEngComm, 21(30), pp.4465-4472.

El-Badry, M., Fathy, M. & Mahrous, G.M., 2015. Preparation and characterization of aceclofenac-sucralose co-crystals for enhancement of dissolution rate. AAPS PharmSciTech, 16(6), pp.12411252. https://doi.org/10.1208/s12249-015-0313-1

Fehrenbacher, J.C. & McCarson, K.E., 2021. Models of inflammation: carrageenan air pouch. Current Protocols, 1(8), e183.

Grover, A., Pawar, E., Singh, G.K., Gupta, A., Pareek, A., Desai, R. & Purkait, I., 2022. Aceclofenac, a preferential COX-2 inhibitor-appraisal of safety and tolerability. Journal of Evolution of Medical and Dental Sciences, 11(7), pp.690-698.

Guo, M., Sun, X., Chen, J. & Cai, T., 2021. Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications. Acta Pharmaceutica Sinica B, 11(8), pp.2537-2564.

Iolascon, G., Gimenez, S. & Mogyorosi, D., 2021. A review of aceclofenac: analgesic and anti-inflammatory effects on musculoskeletal disorders. Journal of Pain Research, pp.3651-3663.

Koirala, S., Nepal, P., Ghimire, G., Basnet, R., Rawat, I., Dahal, A. et al., 2021. Formulation and evaluation of mucoadhesive buccal tablets of aceclofenac. Heliyon, 7(3), e06336.

Martin, S.W., Stevens, A.J., Brennan, B.S., Davies, D., Rowland, M. & Houston, J.B., 1994. The six-day-old rat air pouch model of inflammation: characterization of the inflammatory response to carrageenan. Journal of Pharmacological and Toxicological Methods, 32(3), pp.139-147.

Savjani, K.T., Gajjar, A.K. & Savjani, J.K., 2012. Drug solubility: importance and enhancement techniques. ISRN Pharmaceutics, Article ID 195727. https://doi.org/10.5402/2012/195727

Taskiran, S.Y., Taskiran, M., Unal, G., Bozkurt, N.M. & Golgeli, A., 2023. The long-lasting effects of aceclofenac, a COX-2 inhibitor, in a Poly I:C-induced maternal immune activation model of schizophrenia in rats. Behavioural Brain Research, 452, 114565.

Usman, H., Aldi, Y., Umar, S., Siregar, M.N. & Zaini, E., 2025. Multicomponent crystal of aceclofenac with saccharin to improve solubility and dissolution rate. Multicomponent Crystal of Aceclofenac with Saccharin to Improve Solubility and Dissolution Rate. International Journal of Drug Delivery Technology. 2025;15(2): 630-34. doi:10.25258/ijddt.15.2.32

Downloads

Published

2025-06-30

Issue

Section

Articles

How to Cite

Comparative Anti-Inflammatory Effect of Aceclofenac-Saccharin in Mice Granuloma Model. (2025). Pharmaceutical and Biomedical Sciences Journal (PBSJ), 7(1), 119-123. https://doi.org/10.15408/pbsj.v7i1.49145